0	12	Differential	differential	JJ
13	20	nuclear	nuclear	JJ
21	33	localization	localization	NN
34	36	of	of	IN
37	40	p50	p50	NN
40	41	,	,	,
42	45	p52	p52	NN
45	46	,	,	,
47	50	and	and	CC
51	55	RelB	RelB	NNP
56	64	proteins	protein	NNS
65	67	in	in	IN
68	73	human	human	JJ
74	83	accessory	accessory	JJ
84	89	cells	cell	NNS
90	92	of	of	IN
93	96	the	the	DT
97	103	immune	immune	JJ
104	112	response	response	NN
113	115	in	in	FW
116	120	situ	situ	FW
120	121	.	.	.

123	126	The	the	DT
127	139	Rel/NF-kappa	Rel/NF-kappa	NNP
140	141	B	B	NNP
142	150	proteins	protein	NNS
150	151	,	,	,
152	155	p50	p50	NN
155	156	,	,	,
157	160	p52	p52	NN
160	161	,	,	,
162	165	p65	p65	NN
165	166	,	,	,
167	172	c-Rel	c-rel	NN
172	173	,	,	,
174	177	and	and	CC
178	182	RelB	RelB	NNP
182	183	,	,	,
184	194	constitute	constitute	VBP
195	196	a	a	DT
197	203	family	family	NN
204	206	of	of	IN
207	220	transcription	transcription	NN
221	228	factors	factor	NNS
229	237	involved	involve	VBN
238	240	in	in	IN
241	244	the	the	DT
245	253	positive	positive	JJ
254	264	regulation	regulation	NN
265	267	of	of	IN
268	269	a	a	DT
270	277	variety	variety	NN
278	280	of	of	IN
281	286	genes	gene	NNS
287	293	during	during	IN
294	297	the	the	DT
298	304	immune	immune	JJ
305	313	response	response	NN
313	314	.	.	.

315	323	Recently	recently	RB
323	324	,	,	,
325	327	it	it	PRP
328	331	has	have	VBZ
332	336	been	be	VBN
337	342	shown	show	VBN
343	347	that	that	IN
348	352	RelB	RelB	NNP
353	361	knockout	knockout	NN
362	366	mice	mouse	NNS
367	371	have	have	VBP
372	374	no	no	DT
375	384	dendritic	dendritic	JJ
385	390	cells	cell	NNS
391	392	(	(	(
392	394	DC	DC	NNP
394	395	)	)	)
395	396	.	.	.

397	399	An	an	DT
400	414	overexpression	overexpression	NN
415	417	of	of	IN
418	421	p50	p50	NN
422	425	has	have	VBZ
426	430	been	be	VBN
431	440	described	describe	VBN
441	443	in	in	IN
444	454	follicular	follicular	JJ
455	464	dendritic	dendritic	JJ
465	470	cells	cell	NNS
471	472	(	(	(
472	475	FDC	FDC	NNP
475	476	)	)	)
476	477	.	.	.

478	479	A	a	DT
480	492	constitutive	constitutive	JJ
493	501	NF-kappa	NF-kappa	NNP
502	503	B	B	NNP
504	512	activity	activity	NN
513	516	has	have	VBZ
517	521	been	be	VBN
522	530	reported	report	VBN
531	533	in	in	IN
534	540	mature	mature	JJ
541	552	macrophages	macrophage	NNS
552	553	.	.	.

554	558	This	this	DT
559	562	led	lead	VBD
563	565	to	to	TO
566	569	the	the	DT
570	580	hypothesis	hypothesis	NN
581	585	that	that	IN
586	590	some	some	DT
591	593	of	of	IN
594	597	the	the	DT
598	610	Rel/NF-kappa	Rel/NF-kappa	NNP
611	612	B	B	NNP
613	621	proteins	protein	NNS
622	626	were	be	VBD
627	630	key	key	JJ
631	638	nuclear	nuclear	JJ
639	646	factors	factor	NNS
647	649	in	in	IN
650	659	functions	function	NNS
660	662	of	of	IN
663	672	accessory	accessory	JJ
673	678	cells	cell	NNS
679	681	of	of	IN
682	685	the	the	DT
686	692	immune	immune	JJ
693	701	response	response	NN
701	702	.	.	.

703	712	Therefore	therefore	RB
712	713	,	,	,
714	716	we	we	PRP
717	729	investigated	investigate	VBD
730	732	in	in	FW
733	737	situ	situ	FW
738	741	the	the	DT
742	749	nuclear	nuclear	JJ
750	762	localization	localization	NN
763	765	of	of	IN
766	778	Rel/NF-kappa	Rel/NF-kappa	NNP
779	780	B	B	NNP
781	789	proteins	protein	NNS
790	792	in	in	IN
793	802	accessory	accessory	JJ
803	808	cells	cell	NNS
809	811	of	of	IN
812	815	the	the	DT
816	822	immune	immune	JJ
823	829	system	system	NN
830	832	by	by	IN
833	853	immunohistochemistry	immunohistochemistry	NN
854	857	and	and	CC
858	864	double	double	JJ
865	873	labeling	labeling	NN
874	876	by	by	IN
877	895	immunofluorescence	immunofluorescence	NN
896	900	from	from	IN
901	905	five	five	CD
906	912	normal	normal	JJ
913	918	human	human	JJ
919	926	tonsils	tonsil	NNS
927	930	and	and	CC
931	935	five	five	CD
936	941	lymph	lymph	NN
942	947	nodes	node	NNS
948	952	with	with	IN
953	963	follicular	follicular	JJ
964	975	hyperplasia	hyperplasia	NN
975	976	.	.	.

977	984	Nuclear	nuclear	JJ
985	988	p65	p65	NN
989	992	and	and	CC
993	998	c-Rel	c-rel	NN
999	1007	proteins	protein	NNS
1008	1012	were	be	VBD
1013	1018	found	find	VBN
1019	1021	in	in	IN
1022	1025	all	all	DT
1026	1030	cell	cell	NN
1031	1036	types	type	NNS
1037	1046	including	include	VBG
1047	1058	lymphocytes	lymphocyte	NNS
1058	1059	.	.	.

1060	1062	In	in	IN
1063	1071	germinal	germinal	JJ
1072	1079	centers	center	NNS
1080	1082	GC	GC	NNP
1082	1083	,	,	,
1084	1087	p50	p50	NN
1087	1088	,	,	,
1089	1092	p52	p52	NN
1092	1093	,	,	,
1094	1097	and	and	CC
1098	1102	RelB	RelB	NNP
1103	1107	were	be	VBD
1108	1113	found	find	VBN
1114	1116	in	in	IN
1117	1120	the	the	DT
1121	1127	nuclei	nucleus	NNS
1128	1130	of	of	IN
1131	1134	FDC	FDC	NNP
1135	1139	only	only	RB
1140	1143	and	and	CC
1144	1148	were	be	VBD
1149	1152	not	not	RB
1153	1161	detected	detect	VBN
1162	1164	in	in	IN
1165	1168	the	the	DT
1169	1175	nuclei	nucleus	NNS
1176	1178	of	of	IN
1179	1184	CD68+	cd68+	JJ
1185	1190	cells	cell	NNS
1190	1191	.	.	.

1192	1194	In	in	IN
1195	1196	T	t	NN
1197	1201	cell	cell	NN
1202	1207	areas	area	NNS
1207	1208	,	,	,
1209	1212	p50	p50	NN
1212	1213	,	,	,
1214	1217	p52	p52	NN
1217	1218	,	,	,
1219	1222	and	and	CC
1223	1227	RelB	RelB	NNP
1228	1232	were	be	VBD
1233	1238	found	find	VBN
1239	1241	in	in	IN
1242	1245	the	the	DT
1246	1252	nuclei	nucleus	NNS
1253	1255	of	of	IN
1256	1263	HLA-DR+	hla-dr+	JJ
1264	1269	cells	cell	NNS
1270	1274	with	with	IN
1275	1277	an	an	DT
1278	1296	antigen-presenting	antigen-presenting	JJ
1297	1301	cell	cell	NN
1302	1303	(	(	(
1303	1306	APC	APC	NNP
1306	1307	)	)	)
1308	1319	morphology.	morphology.	NN
1320	1323	p52	p52	NN
1324	1327	and	and	CC
1328	1332	RelB	RelB	NNP
1333	1337	were	be	VBD
1338	1346	detected	detect	VBN
1347	1349	in	in	IN
1350	1353	the	the	DT
1354	1360	nuclei	nucleus	NNS
1361	1363	in	in	IN
1364	1368	both	both	CC
1369	1374	CD1a+	cd1a+	JJ
1375	1378	and	and	CC
1379	1384	CD68+	cd68+	JJ
1385	1390	cells	cell	NNS
1391	1395	from	from	IN
1396	1399	the	the	DT
1400	1401	T	t	NN
1402	1406	cell	cell	NN
1407	1411	area	area	NN
1411	1412	,	,	,
1413	1420	whereas	whereas	IN
1421	1424	p50	p50	NN
1425	1428	was	be	VBD
1429	1434	found	find	VBN
1435	1439	only	only	RB
1440	1442	in	in	IN
1443	1448	CD68-	cd68-	JJ
1449	1452	and	and	CC
1453	1458	CD1a-	cd1a-	JJ
1459	1464	cells	cell	NNS
1464	1465	.	.	.

1466	1471	Cells	cell	NNS
1472	1476	with	with	IN
1477	1484	nuclear	nuclear	JJ
1485	1488	p50	p50	NN
1489	1493	were	be	VBD
1494	1502	negative	negative	JJ
1503	1506	for	for	IN
1507	1510	the	the	DT
1511	1515	CD38	cd38	NN
1515	1516	,	,	,
1517	1521	CD20	CD20	NNP
1522	1525	and	and	CC
1526	1529	CD2	cd2	NN
1530	1537	markers	marker	NNS
1537	1538	.	.	.

1539	1544	These	these	DT
1545	1552	results	result	NNS
1553	1557	show	show	VBP
1558	1562	that	that	IN
1562	1563	,	,	,
1564	1579	physiologically	physiologically	RB
1579	1580	,	,	,
1581	1585	high	high	JJ
1586	1592	levels	level	NNS
1593	1595	of	of	IN
1596	1603	nuclear	nuclear	JJ
1604	1606	of	of	IN
1607	1610	p50	p50	NN
1610	1611	,	,	,
1612	1615	p52	p52	NN
1616	1619	and	and	CC
1620	1624	RelB	RelB	NNP
1625	1628	are	be	VBP
1629	1639	restricted	restricted	JJ
1640	1642	to	to	TO
1643	1652	accessory	accessory	JJ
1653	1658	cells	cell	NNS
1659	1661	of	of	IN
1662	1665	the	the	DT
1666	1672	immune	immune	JJ
1673	1679	system	system	NN
1679	1680	,	,	,
1681	1686	which	which	WDT
1687	1694	include	include	VBP
1695	1698	FDC	FDC	NNP
1699	1701	in	in	IN
1702	1704	GC	GC	NNP
1704	1705	,	,	,
1706	1709	and	and	CC
1710	1712	DC	DC	NNP
1713	1716	and	and	CC
1717	1728	macrophages	macrophage	NNS
1729	1731	in	in	IN
1732	1735	the	the	DT
1736	1737	T	t	NN
1738	1742	cell	cell	NN
1743	1747	zone	zone	NN
1747	1748	,	,	,
1749	1753	that	that	WDT
1754	1765	specialized	specialize	VBD
1766	1775	scavenger	scavenger	NN
1776	1787	macrophages	macrophage	NNS
1788	1792	from	from	IN
1793	1795	GC	GC	NNP
1796	1798	do	do	VBP
1799	1802	not	not	RB
1803	1807	have	have	VB
1808	1818	detectable	detectable	JJ
1819	1825	levels	level	NNS
1826	1828	of	of	IN
1829	1832	p52	p52	NN
1833	1836	and	and	CC
1837	1841	RelB	RelB	NNP
1841	1842	,	,	,
1843	1850	whereas	whereas	IN
1851	1862	macrophages	macrophage	NNS
1863	1867	from	from	IN
1868	1871	the	the	DT
1872	1873	T	t	NN
1874	1878	cell	cell	NN
1879	1883	area	area	NN
1883	1884	,	,	,
1885	1890	known	know	VBN
1891	1893	to	to	TO
1894	1901	present	present	VB
1902	1905	the	the	DT
1906	1913	antigen	antigen	NN
1914	1916	to	to	TO
1917	1918	T	t	NN
1919	1924	cells	cell	NNS
1924	1925	,	,	,
1926	1928	do	do	VBP
1929	1933	have	have	VB
1934	1938	both	both	CC
1939	1946	nuclear	nuclear	JJ
1947	1950	p52	p52	NN
1951	1954	and	and	CC
1955	1959	RelB	RelB	NNP
1959	1960	,	,	,
1961	1964	and	and	CC
1965	1969	that	that	IN
1970	1972	in	in	IN
1973	1976	the	the	DT
1977	1978	T	t	NN
1979	1983	cell	cell	NN
1984	1988	zone	zone	NN
1988	1989	,	,	,
1990	1993	p52	p52	NN
1994	1997	and	and	CC
1998	2002	RelB	RelB	NNP
2003	2006	are	be	VBP
2007	2014	located	located	JJ
2015	2017	in	in	IN
2018	2024	nuclei	nucleus	NNS
2025	2027	of	of	IN
2028	2032	both	both	CC
2033	2038	CD1a+	cd1a+	JJ
2038	2039	,	,	,
2040	2045	CD68+	cd68+	JJ
2046	2048	or	or	CC
2049	2053	both	both	DT
2053	2054	,	,	,
2055	2060	cells	cell	NNS
2061	2064	APC	APC	NNP
2064	2065	,	,	,
2066	2073	whereas	whereas	IN
2074	2077	p50	p50	NN
2078	2080	is	be	VBZ
2081	2091	restricted	restricted	JJ
2092	2094	to	to	TO
2095	2100	CD1a-	CD1a-	NNP
2101	2104	and	and	CC
2105	2110	CD68-	cd68-	JJ
2111	2114	APC	APC	NNP
2114	2115	.	.	.

2116	2119	The	the	DT
2120	2129	different	different	JJ
2130	2138	patterns	pattern	NNS
2139	2141	of	of	IN
2142	2145	p50	p50	NN
2145	2146	,	,	,
2147	2150	p52	p52	NN
2151	2154	and	and	CC
2155	2159	RelB	RelB	NNP
2160	2167	protein	protein	NN
2168	2175	nuclear	nuclear	JJ
2176	2188	localization	localization	NN
2189	2192	may	may	MD
2193	2200	provide	provide	VB
2201	2208	insight	insight	NN
2209	2213	into	into	IN
2214	2219	their	their	PRP$
2220	2229	different	different	JJ
2230	2235	roles	role	NNS
2236	2242	during	during	IN
2243	2246	the	the	DT
2247	2253	immune	immune	JJ
2254	2262	response	response	NN
2263	2265	in	in	FW
2266	2270	vivo	vivo	FW
2270	2271	.	.	.